Kynam Capital Management, LP 13F Portfolio

CIK 1907884 Filing since Q4 2021 Q3 2026 filed Nov 16, 2026
Holdings as of Sep 30, 2026, from the 13F filed Nov 16, 2026.

Portfolio Snapshot

33 positions · Q3 2026

Kynam Capital Management, LP reported 33 positions worth $1.81B for the quarter ended Sep 30, 2026, down 0.2% on the prior quarter. It opened 4 new positions, added to 8, trimmed 6 and exited 2. Its largest holding is Legend Biotech Corp at 10.1% of the portfolio.

Portfolio Value
$1.81B
-0.2% QoQ · +39.3% YoY
Positions
33
4 new · 2 sold out
Top 10 Concentration
72.3%
of portfolio value
Largest Position
LEGN 10.1%
Legend Biotech Corp
Net Buying
+$178.90M
$234.90M bought · $56.00M sold
Turnover
3.1%
of the portfolio traded
Top Sector
Healthcare
100% of value
Track Record
20
quarters on file since Q4 2021

Portfolio Value & Positions

Value Positions

Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.

Sector Allocation

1 sectors
100%
Healthcare
Healthcare100%

Quarterly Buying & Selling

Bought Sold

Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.

Position Changes

How many positions were opened, added to, trimmed or closed each quarter.

Sector Allocation Over Time

Share of reported value in each sector at every quarter end.

HealthcareOther

Largest Buys

Q3 2026
Holding Change Change % Trade Value Weight
LEGN Legend Biotech Corp +6.15M +205.0% $122.39M 10.08%
SMMT Summit Therapeutics Inc. +1.80M +150.0% $30.44M 2.81%
BEAM Beam Therapeutics Inc. +1.09M +38.5% $26.73M 5.33%
SRZN Surrozen, Inc. +486.3K – $15.65M 0.866%
XENE Xenon Pharmaceuticals Inc. +280.0K – $10.41M 0.577%
EVMN Evommune, Inc. +1.20M – $9.91M 0.549%
PHVS Pharvaris N.V. +163.0K +24.6% $5.17M 1.45%
COGT Cogent Biosciences, Inc. +125.2K +3.4% $4.01M 6.72%
HROW Harrow, Inc. +124.7K – $3.84M 0.213%
VERA Vera Therapeutics, Inc. +109.9K +3.8% $3.55M 5.36%

Largest Sells

Q3 2026
Holding Change Change % Trade Value Weight
PCVX Vaxcyte, Inc. -314.4K -10.8% $17.89M 8.22%
INSM INSMED Inc -100.0K -100.0% $10.66M Exited
RLAY Relay Therapeutics, Inc. -548.5K -16.6% $9.90M 2.75%
CLDX Celldex Therapeutics, Inc. -256.9K -4.8% $8.32M 9.09%
VRDN Viridian Therapeutics, Inc.DE -305.9K -4.7% $6.30M 7.01%
CTMX CytomX Therapeutics, Inc. -562.4K -2.6% $1.53M 3.18%
CADL Candel Therapeutics, Inc. -96.7K -100.0% $996.43K Exited
PRLD Prelude Therapeutics Inc -103.1K -4.3% $403.25K 0.501%

New Positions

Q3 2026
Holding Shares Trade Value Weight
SRZN Surrozen, Inc. +486.3K $15.65M 0.866%
XENE Xenon Pharmaceuticals Inc. +280.0K $10.41M 0.577%
EVMN Evommune, Inc. +1.20M $9.91M 0.549%
HROW Harrow, Inc. +124.7K $3.84M 0.213%

Closed Positions

Q3 2026
Holding Shares Sold Trade Value Prior Weight
INSM INSMED Inc -100.0K $10.66M 0.589%
CADL Candel Therapeutics, Inc. -96.7K $996.43K 0.055%
Holdings · Q3 2026

33 Positions

As ofSep 30, 2026
Value$1.81B
Top 1072.3%
Avg position$54.73M
# Activity
18 more holdings Create a free account to keep reading this institution’s full portfolio.
Showing 1–15 of 33 positions 13F filings on SEC EDGAR

Tip. Select a row to see that position’s full history at Kynam Capital Management.

About Kynam Capital Management, LP’s 13F Portfolio

What are Kynam Capital Management, LP’s largest holdings?

As of its Q3 2026 13F filing, Kynam Capital Management, LP’s five largest positions were Legend Biotech Corp (LEGN) at 10.1%, Celldex Therapeutics, Inc. (CLDX) at 9.1%, Syndax Pharmaceuticals Inc (SNDX) at 8.5%, Vaxcyte, Inc. (PCVX) at 8.2%, Viridian Therapeutics, Inc.DE (VRDN) at 7.0% of the reported portfolio.

How much is Kynam Capital Management, LP’s portfolio worth?

Kynam Capital Management, LP reported a 13F portfolio worth $1.81B across 33 positions for Q3 2026. That is down 0.2% from the previous quarter.

What did Kynam Capital Management, LP buy in Q3 2026?

Its largest purchases by value were Legend Biotech Corp ($122.39M), Summit Therapeutics Inc. ($30.44M), Beam Therapeutics Inc. ($26.73M). It opened 4 new positions.

What did Kynam Capital Management, LP sell in Q3 2026?

Its largest sales by value were Vaxcyte, Inc. ($17.89M), INSMED Inc ($10.66M), Relay Therapeutics, Inc. ($9.90M). It exited 2 positions entirely.

Where does this data come from?

From the Form 13F-HR reports Kynam Capital Management, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.

Similar-Sized Institutions

by reported 13F value

13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.